Formulary Watch |

All News - Page 10

Tan-stock.adobe.com
Newly Approved Vaccines Face a Fragmented Policy Landscape
Newly Approved Vaccines Face a Fragmented Policy Landscape
February 13, 2024
The Inflation Reduction Act has helped to close some of the gaps in insurance coverage for vaccines, including some of the newly approved ones.
 Express Scripts Adds Voquezna to Formulary for Gastroesophageal Reflux
 Express Scripts Adds Voquezna to Formulary for Gastroesophageal Reflux
Express Scripts Adds Voquezna to Formulary for Gastroesophageal Reflux
February 13, 2024
Voquezna is a potassium-competitive acid blocker, which has a mechanism similar to proton pump inhibitors but with a more rapid action. It has a list price of $650 for a 30-count bottle.
CVS’s Health Services Revenue Grew to $186.8 Billion
CVS’s Health Services Revenue Grew to $186.8 Billion
CVS’s Health Services Revenue Grew to $186.8 Billion
February 8, 2024
CVS’s Health Services segment — which includes its PBM CVS Caremark — now accounts for more than half of CVS’s total revenue.
HHS: Patients Should Not Face High Copays for Paxlovid
HHS: Patients Should Not Face High Copays for Paxlovid
HHS: Patients Should Not Face High Copays for Paxlovid
February 8, 2024
Although HHS is no longer managing the distribution of COVID-19 drugs, Secretary Xavier Becerra has been closely monitoring distribution of the antivirals Paxlovid and Lagevrio.
Trifonenko Ivan-stock.adobe.com
Survey: Many Support Medicare Coverage of Weight Loss Drugs
Survey: Many Support Medicare Coverage of Weight Loss Drugs
February 7, 2024
Although most older adults support Medicare coverage of medications for weight loss drugs, only one in three favor paying more in premiums for this coverage, finds University of Michigan survey.
Evernorth is “Foundational” to Cigna’s Business
Evernorth is “Foundational” to Cigna’s Business
Evernorth is “Foundational” to Cigna’s Business
February 2, 2024
The bulk of Cigna’s $195.3 billion 2023 revenue comes from Evernorth. And Cigna is positioning itself to grow Evernorth even more.
 stas_malyarevsky-stock.adobe.com
Medicare Drug Price Negotiation Begins Today
Medicare Drug Price Negotiation Begins Today
February 1, 2024
New research finds that in 2022, U.S. prices across all drugs were almost three times higher than in other countries.
Biogen to Stop Selling Alzheimer’s Drug Aduhelm
Biogen to Stop Selling Alzheimer’s Drug Aduhelm
Biogen to Stop Selling Alzheimer’s Drug Aduhelm
January 31, 2024
Biogen will focus its resources on Leqembi and research of other treatments for Alzheimer’s disease.
AIGen-stock.adobe.com
FDA Warns About Malignancies from CAR-T Therapies
FDA Warns About Malignancies from CAR-T Therapies
January 26, 2024
The FDA orders new warnings for CAR-T cell therapies due to reports of T-cell malignancies, including fatal cases, applying to BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.
Tyson Foods Selects Rightway as its PBM over CVS Caremark
Tyson Foods Selects Rightway as its PBM over CVS Caremark
Tyson Foods Selects Rightway as its PBM over CVS Caremark
January 25, 2024
CVS Caremark will continue to manage specialty drug benefits for Tyson Foods.
Drug Price Transparency Takes a Coalition
Drug Price Transparency Takes a Coalition
Drug Price Transparency Takes a Coalition
January 25, 2024
Joseph M. Shields talks about the formation of Transparency-Rx and its goals of achieving PBM reform that focuses on “corrective steps to address the misalignment in the marketplace to ensure that there’s competition and choice.”
anatolir-stock.adobe.com
HHS Reminds Plans to Provide Coverage for Contraception
HHS Reminds Plans to Provide Coverage for Contraception
January 24, 2024
Coverage of contraceptives and contraceptive care without cost-sharing is required under the Affordable Care Act.
10 State Medicaid Programs Include Pheburane for Urea Cycle Disorders
10 State Medicaid Programs Include Pheburane for Urea Cycle Disorders
10 State Medicaid Programs Include Pheburane for Urea Cycle Disorders
January 23, 2024
Current treatments for urea cycle disorders, which causes ammonia to build up in the blood, have a bitter taste and smell. Pheburane was developed with a special coating that masks the taste of sodium phenylbutyrate. It has a list price of $4,375 per bottle.
Will Patients Benefit from Drug Price Negotiations?
Will Patients Benefit from Drug Price Negotiations?
Will Patients Benefit from Drug Price Negotiations?
January 22, 2024
Peter Rubin of No Patient Left Behind worries that patients may not see benefits, either in lowered costs or continued investment in new therapies, from drug price negotiations required under the Inflation Reduction Act.
© 2024 MJH Life Sciences

All rights reserved.